A Novel Tool to Predict the Overall Survival of High-Grade Osteosarcoma Patients after Neoadjuvant Chemotherapy: A Large Population-Based Cohort Study

Figure 6

Decision curve analysis depicting the net clinical benefit of OS at 3 (a), 5 (b), and 8 (c) years for the validation cohort. OS, overall survival.

(a)

(b)

(c)